Company Profile

Pherecydes Pharma SA specializes in research into innovative and adaptive solutions to fight multi-resistant bacterial infections, using cocktails of natural phages. Thanks to its unique expertise, Pherecydes Pharma has managed to develop a large bank of bacteriophages cocktails to fight antibiotic-resistant infections, steadily on the rise since the 1980s. The company owns a vast collection of phages against Escherichia coli (E.coli), Pseudomonas and staphylococcal infections. These three species are responsible for more than 50% of bacterial infections in industrialized countries. Half a dozen patents have been filed or are in the process of being registered in order to protect the technology and products developed by Pherecydes Pharma. In addition to the two products being tested in the Phagoburn clinical trial, the company is developing two other products: one for the treatment of respiratory tract infections and the other for bone and joint infections and diabetic ulcers. Located in the Biocitech science park near Paris, Pherecydes Pharma has twelve employees. In addition to capital rounds, it also benefits from public funding from the Ministry of Defense (PneumoPhage project), the Single Inter-Ministry Fund (Phosa project) and the European FP7 grant for the Phagoburn project.